Decibel Therapeutics, Inc. Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 51 rows, 51 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2021-03-08: Reporting owner Schroder Adveq cPl Global 2017 - 2019 C.V. | Schroder Adveq Management Luxembourg Sarl | Schroder Adveq cPl Global Management III L.P. | Schroder Adveq Technology IX S.C.S.; Form 3; Security Series C Preferred Stock; Transaction Holding.
- 2021-03-08: Reporting owner Schroder Adveq cPl Global 2017 - 2019 C.V. | Schroder Adveq Management Luxembourg Sarl | Schroder Adveq cPl Global Management III L.P. | Schroder Adveq Technology IX S.C.S.; Form 3; Security Series C Preferred Stock; Transaction Holding.
- 2021-02-17: Reporting owner Schroder Adveq cPl Global Management III L.P. | Schroder Adveq Technology IX S.C.S. | Schroder Adveq Management Luxembourg Sarl | Schroder Adveq cPl Global 2017 - 2019 C.V.; Form 4; Security Series C Preferred Stock; Transaction C Conversion of derivative security.
- 2021-02-17: Reporting owner Schroder Adveq cPl Global Management III L.P. | Schroder Adveq Technology IX S.C.S. | Schroder Adveq Management Luxembourg Sarl | Schroder Adveq cPl Global 2017 - 2019 C.V.; Form 4; Security Series C Preferred Stock; Transaction C Conversion of derivative security.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2021-03-08 holding as of filing | Schroder Adveq cPl Global 2017 - 2019 C.V. | Schroder Adveq Management Luxembourg Sarl | Schroder Adveq cPl Global Management III L.P. | Schroder Adveq Technology IX S.C.S. 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-03-08 | ||
| 2021-03-08 holding as of filing | Schroder Adveq cPl Global 2017 - 2019 C.V. | Schroder Adveq Management Luxembourg Sarl | Schroder Adveq cPl Global Management III L.P. | Schroder Adveq Technology IX S.C.S. 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-03-08 | ||
| 2021-02-17 | Schroder Adveq cPl Global Management III L.P. | Schroder Adveq Technology IX S.C.S. | Schroder Adveq Management Luxembourg Sarl | Schroder Adveq cPl Global 2017 - 2019 C.V. 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series C Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −6,625,001 0 owned after | no price filed | 2021-03-08 | |
| 2021-02-17 | Schroder Adveq cPl Global Management III L.P. | Schroder Adveq Technology IX S.C.S. | Schroder Adveq Management Luxembourg Sarl | Schroder Adveq cPl Global 2017 - 2019 C.V. 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series C Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −6,625,001 0 owned after | no price filed | 2021-03-08 | |
| 2021-02-17 | ORBIMED ADVISORS LLC | OrbiMed Capital GP VIII LLC | ORBIMED CAPITAL LLC | OrbiMed Genesis GP LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnotes | C Conversion of derivative security | −14,480,162 0 owned after | $0.00 | 2021-02-19 | |
| 2021-02-17 | ORBIMED ADVISORS LLC | OrbiMed Capital GP VIII LLC | ORBIMED CAPITAL LLC | OrbiMed Genesis GP LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnotes | C Conversion of derivative security | −1,737,619 0 owned after | $0.00 | 2021-02-19 | |
| 2021-02-17 | ORBIMED ADVISORS LLC | OrbiMed Capital GP VIII LLC | ORBIMED CAPITAL LLC | OrbiMed Genesis GP LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnotes | C Conversion of derivative security | −1,158,412 0 owned after | $0.00 | 2021-02-19 | |
| 2021-02-17 | Foy Matthew Director, 10% Owner | 4 | Series A Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −7,119,852 0 owned after | $0.00 | 2021-02-19 | |
| 2021-02-17 | Foy Matthew Director, 10% Owner | 4 | Series C Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −3,125,000 0 owned after | $0.00 | 2021-02-19 | |
| 2021-02-17 | Foy Matthew Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −1,737,619 0 owned after | $0.00 | 2021-02-19 | |
| 2021-02-17 | Casdin Partners Master Fund, L.P. 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −2,896,032 0 owned after | $0.00 | 2021-02-19 | |
| 2021-02-17 | Thompson Peter A. Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −14,480,162 0 owned after | $0.00 | 2021-02-19 | |
| 2021-02-17 | Thompson Peter A. Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −1,737,619 0 owned after | $0.00 | 2021-02-19 | |
| 2021-02-17 | Thompson Peter A. Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −1,158,412 0 owned after | $0.00 | 2021-02-19 | |
| 2021-02-17 | Exter Neil Director, 10% Owner | 4 | Series A Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −45,638,882 0 owned after | $0.00 | 2021-02-19 | |
| 2021-02-17 | Exter Neil Director, 10% Owner | 4 | Series C Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −1,250,000 0 owned after | $0.00 | 2021-02-19 | |
| 2021-02-17 | Exter Neil Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −289,603 0 owned after | $0.00 | 2021-02-19 | |
| 2021-02-17 | GLAXOSMITHKLINE PLC Director | 4 | Series A Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −7,119,850 0 owned after | no price filed | 2021-02-19 | |
| 2021-02-17 | GLAXOSMITHKLINE PLC Director | 4 | Series C Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −3,125,000 0 owned after | no price filed | 2021-02-19 | |
| 2021-02-17 | GLAXOSMITHKLINE PLC Director | 4 | Series D Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −1,737,619 0 owned after | no price filed | 2021-02-19 | |
| 2021-02-17 | Longevity Fund 2 LP 10% Owner | 4 | Convertible Series C Preferred Stock Derivative · Direct | C Conversion of derivative security | −79,143 0 owned after | $0.00 | 2021-02-18 | |
| 2021-02-17 | REGENERON PHARMACEUTICALS, INC. 10% Owner | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −12,500,000 0 owned after | $0.00 | 2021-02-18 | |
| 2021-02-17 | REGENERON PHARMACEUTICALS, INC. 10% Owner | 4 | Series C Preferred Stock Derivative · Direct | C Conversion of derivative security | −14,000,000 0 owned after | $0.00 | 2021-02-18 | |
| 2021-02-17 | GV 2019 GP, L.L.C. | GV 2019 GP, L.P. | GV 2019, L.P. 10% Owner | 10% Owner | 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · By GV 2019, L.P. | C Conversion of derivative security | −4,344,048 0 owned after | no price filed | 2021-02-17 | |
| 2021-02-17 | GV 2017, L.P. | GV 2017 GP, L.L.C. | GV 2017 GP, L.P. 10% Owner | 10% Owner | 10% Owner | 4 | Series C Preferred Stock Derivative · Indirect · By GV 2017, L.P. | C Conversion of derivative security | −6,250,000 0 owned after | no price filed | 2021-02-17 | |
| 2021-02-17 | GV 2016, L.P. | GV 2016 GP, L.L.C. | GV 2016 GP, L.P. 10% Owner | 10% Owner | 10% Owner | 4 | Series A Preferred Stock Derivative · Indirect · By GV 2016, L.P. | C Conversion of derivative security | −5,000,000 0 owned after | no price filed | 2021-02-17 | |
| 2021-02-12 holding as of filing | TEPPER ROBERT I | STARR KEVIN P | LEVIN MARK J | Third Rock Ventures III, L.P. | Third Rock Ventures GP III, L.P. | TRV GP III, LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series A Convertible Preferred Stock Derivative · Direct | Holding | no price filed | 2021-02-12 | ||
| 2021-02-12 holding as of filing | TEPPER ROBERT I | STARR KEVIN P | LEVIN MARK J | Third Rock Ventures III, L.P. | Third Rock Ventures GP III, L.P. | TRV GP III, LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series C Convertible Preferred Stock Derivative · Direct | Holding | no price filed | 2021-02-12 | ||
| 2021-02-12 holding as of filing | TEPPER ROBERT I | STARR KEVIN P | LEVIN MARK J | Third Rock Ventures III, L.P. | Third Rock Ventures GP III, L.P. | TRV GP III, LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series D Convertible Preferred Stock Derivative · Direct | Holding | no price filed | 2021-02-12 | ||
| 2021-02-11 holding as of filing | Casdin Partners Master Fund, L.P. 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | OrbiMed Genesis GP LLC | ORBIMED CAPITAL LLC | OrbiMed Capital GP VIII LLC | ORBIMED ADVISORS LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnotes | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | OrbiMed Genesis GP LLC | ORBIMED CAPITAL LLC | OrbiMed Capital GP VIII LLC | ORBIMED ADVISORS LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnotes | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | OrbiMed Genesis GP LLC | ORBIMED CAPITAL LLC | OrbiMed Capital GP VIII LLC | ORBIMED ADVISORS LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnotes | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | Foy Matthew Director, 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | Foy Matthew Director, 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | Foy Matthew Director, 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | Exter Neil Director, 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | Exter Neil Director, 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | Exter Neil Director, 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | Thompson Peter A. Director, 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | Thompson Peter A. Director, 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | Thompson Peter A. Director, 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | GLAXOSMITHKLINE PLC Director, 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | GLAXOSMITHKLINE PLC Director, 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | GLAXOSMITHKLINE PLC Director, 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | Longevity Fund 2 LP 10% Owner | 3 | Convertible Series C Preferred Stock Derivative · Direct | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | GV 2019 GP, L.P. | GV 2019, L.P. | GV 2019 GP, L.L.C. 10% Owner | 10% Owner | 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · By GV 2019, L.P. | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | GV 2017, L.P. | GV 2017 GP, L.L.C. | GV 2017 GP, L.P. 10% Owner | 10% Owner | 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · By GV 2017, L.P. | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | GV 2016 GP, L.P. | GV 2016, L.P. | GV 2016 GP, L.L.C. 10% Owner | 10% Owner | 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · By GV 2016, L.P. | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | REGENERON PHARMACEUTICALS, INC. 10% Owner | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2021-02-11 | ||
| 2021-02-11 holding as of filing | REGENERON PHARMACEUTICALS, INC. 10% Owner | 3 | Series C Preferred Stock Derivative · Direct | Holding | no price filed | 2021-02-11 |